Terminated PHASE3 INTERVENTIONAL 2-arm NCT04390113

Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC)

Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym-M (ALVR105) for the Treatment of Patients With Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplant (HCT)

Sponsor: AlloVir

Conditions BK Virus Infection Hemorrhagic Cystitis

Interventions Placebo Posoleucel (ALVR105)

Updated 13 times since 2020 Last updated: Apr 18, 2024 Started: Mar 18, 2021 Primary completion: Jan 30, 2024 Completion: Jan 30, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study discontinued as DSMB determined it was futile. No safety concerns were noted.

Other terminated trials from AlloVir

More terminations from AlloVir

This PHASE3 trial investigates BK Virus Infection and Hemorrhagic Cystitis and is currently terminated or withdrawn. AlloVir leads this study, which shows 13 recorded versions since 2021 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

13 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jun 2024 — Jul 2024 [monthly]

Terminated PHASE3
Mar 2024 — Jun 2024 [monthly]

Terminated PHASE3

Status: Recruiting → Terminated

▶ Show 8 earlier versions

Feb 2023 — Mar 2024 [monthly]

Recruiting PHASE3
Apr 2022 — Feb 2023 [monthly]

Recruiting PHASE3
Feb 2022 — Apr 2022 [monthly]

Recruiting PHASE3
Nov 2021 — Feb 2022 [monthly]

Recruiting PHASE3
Sep 2021 — Nov 2021 [monthly]

Recruiting PHASE3
Feb 2021 — Sep 2021 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Jan 2021 — Feb 2021 [monthly]

Not Yet Recruiting PHASE3
Jun 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AlloVir

Data source: AlloVir

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Baltimore, United States , Barcelona, Spain , Boston, United States , Bristol, United Kingdom , Buffalo, United States , Chicago, United States , Cleveland, United States , Columbus, United States , Dallas, United States and 35 more locations